PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of	Docket No: Q91925
Jin-Soo KIM, et al.	
Appln. No.: 10/559,806	Group Art Unit: Unknown
Confirmation No.: Unknown	Examiner: Unknown
Filed: December 8, 2005	

For: TRANSDUCIBLE DNA-BINDING PROTEINS

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. H. HARADA et al., "Antitumor Effect of TAT-Oxygen-dependent Degradation-Caspase-3 Fusion Protein Specifically Stabilized and Activated in Hypoxic Tumor Cells", *Cancer Research*, Vol. 62, April 1, 2002, pp. 2013-2018.

2. H. WU et al., "Poly-arginine-fused calpastatin peptide, a living cell membrane-permeable and specific inhibitor for calpain", *Neuroscience Research*, Vol. 47, 2003, pp. 131-135.

3. T. TAKENOBU et al., "Development of p53 Protein Transduction Therapy Using Membrane-permeable Peptides and the Application to Oral Cancer Cells", *Molecular Cancer Therapeutics*, Vol. 1, October 2002, pp. 1043-1049.

4. A. HO et al., "Synthetic Protein Transduction Domains: Enhanced Transduction Potential *in Vitro* and *in Vivo*", *Cancer Research*, Vol. 61, January 15, 2001, pp. 474-477.

5. A.D. FRANKEL et al., "Tat Protein from Human Immunodeficiency Virus Forms a Metal-Linked Dimer", *Science*, Vol. 240, April 1, 1988, pp. 70-73.

6. D.R. GIUS et al., "Transduced $p16^{INK4a}$ Peptides Inhibit Hypophosphorylation of the Retinoblastoma Protein and Cell Cycle Progression Prior to Activation of Cdk2 Complexes in Late G_1", *Cancer Research*, Vol. 59, June 1, 1999, pp. 2577-2580.

7. E.L. Snyder and S.F. Dowdy, "Cell Penetrating Peptides in Drug Delivery", *Pharmaceutical Research*, Vol. 21, No. 3, March 2004, pp. 389-393.

8. A. VOCERO-AKBANI et al., "Transduction of Full-Length Tat Fusion Proteins Directly into Mammalian Cells: Analysis of T Cell Receptor Activation-Induced Cell Death", *Methods in Enzymology*, Vol. 322, 2000, pp. 508-521.

One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



John T. Callahan
Registration No. 32,607

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: April 14, 2006

Substitute for Form 1449 A & B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/559,806
Confirmation Number	Unknown
Filing Date	December 8, 2005
First Named Inventor	Jin-Soo KIM
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q91925

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number	Document Number: Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Foreign Patent Document: Number[4]	Foreign Patent Document: Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation[6]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation[6]
		H. HARADA et al., "Antitumor Effect of TAT-Oxygen-dependent Degradation-Caspase-3 Fusion Protein Specifically Stabilized and Activated in Hypoxic Tumor Cells", *Cancer Research*, Vol. 62, April 1, 2002, pp. 2013-2018	
		H. WU et al., "Poly-arginine-fused calpastatin peptide, a living cell membrane-permeable and specific inhibitor for calpain", *Neuroscience Research*, Vol. 47, 2003, pp. 131-135	
		T. TAKENOBU et al., "Development of p53 Protein Transduction Therapy Using Membrane-permeable Peptides and the Application to Oral Cancer Cells", *Molecular Cancer Therapeutics*, Vol. 1, October 2002, pp. 1043-1049	
		A. HO et al., "Synthetic Protein Transduction Domains: Enhanced Transduction Potential *in Vitro* and *in Vivo*", *Cancer Research*, Vol. 61, January 15, 2001, pp. 474-477	
		A.D. FRANKEL et al., "Tat Protein from Human Immunodeficiency Virus Forms a Metal-Linked Dimer", *Science*, Vol. 240, April 1, 1988, pp. 70-73	
		D.R. GIUS et al., "Transduced $p16^{INK4a}$ Peptides Inhibit Hypophosphorylation of the Retinoblastoma Protein and Cell Cycle Progression Prior to Activation of Cdk2 Complexes in Late G_1", *Cancer Research*, Vol. 59, June 1, 1999, pp. 2577-2580	
		E.L. Snyder and S.F. Dowdy, "Cell Penetrating Peptides in Drug Delivery", *Pharmaceutical Research*, Vol. 21, No. 3, March 2004, pp. 389-393	
		A. VOCERO-AKBANI et al., "Transduction of Full-Length Tat Fusion Proteins Directly into Mammalian Cells: Analysis of T Cell Receptor Activation-Induced Cell Death", *Methods in Enzymology*, Vol. 322, 2000, pp. 508-521	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to indicate here if English language Translation is attached.